4//SEC Filing
Thornton Michael Milos 4
Accession 0001209191-20-035437
CIK 0001681682other
Filed
Jun 9, 8:00 PM ET
Accepted
Jun 10, 7:37 AM ET
Size
7.5 KB
Accession
0001209191-20-035437
Insider Transaction Report
Form 4
Thornton Michael Milos
Chief Technology Officer
Transactions
- Conversion
Common Stock
2020-06-08$0.87/sh+51,747$45,020→ 267,710 total - Conversion
Series A Convertible Preferred Stock
2020-06-08$1143.68/sh−43.719$50,001→ 0 totalExercise: $0.87From: 2019-12-11→ Common Stock (51,747 underlying)
Footnotes (3)
- [F1]Includes unvested restricted stock units.
- [F2]The Series A Convertible Preferred Stock has a face value of $1,000 per share and accrues dividends thereon at an annual rate of 6.0%. The face value plus accrued and unpaid dividends of the Series A Convertible Preferred Stock is convertible into common stock at a price per share of $0.87.
- [F3]The Series A Convertible Preferred Stock has no expiration date.
Documents
Issuer
ENDRA Life Sciences Inc.
CIK 0001681682
Entity typeother
Related Parties
1- filerCIK 0001706297
Filing Metadata
- Form type
- 4
- Filed
- Jun 9, 8:00 PM ET
- Accepted
- Jun 10, 7:37 AM ET
- Size
- 7.5 KB